Company news

DiaMedica Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event

December 12, 2021

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 16, 2021

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results

November 9, 2021

DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

November 8, 2021

DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

November 7, 2021

DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

November 3, 2021

DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021

October 17, 2021

DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke

September 29, 2021

DiaMedica Therapeutics Announces $30 Million Private Placement

September 26, 2021

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

September 12, 2021

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

September 6, 2021

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results

August 10, 2021

DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021

August 4, 2021

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 27, 2021

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

July 14, 2021

DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD

June 28, 2021

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

May 16, 2021

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

May 4, 2021

DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

April 27, 2021

DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update

March 9, 2021

DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021

March 2, 2021

DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study

December 14, 2020

DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke

December 9, 2020

DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results

November 3, 2020

DiaMedica Therapeutics to Report Third Quarter 2020 Financial Results and Provide a Business Update November 5, 2020

October 27, 2020

DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study

September 13, 2020

DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results

August 10, 2020

DiaMedica Announces Closing of $23 Million Public Offering of Common Shares

August 9, 2020

DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares

August 5, 2020

DiaMedica Announces Proposed Public Offering of Common Shares

August 4, 2020

DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results

May 12, 2020

DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study

May 12, 2020

DiaMedica Therapeutics to Report First Quarter 2020 Financial Results and Provide a Business Update May 14, 2020

May 6, 2020

DiaMedica Therapeutics Announces 2019 Financial Results and Provides Business Update

March 22, 2020

DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares

February 12, 2020

DiaMedica Announces Pricing of Public Offering of Common Shares

February 10, 2020

DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

December 16, 2019

DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

November 12, 2019

DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019

November 5, 2019

DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

October 13, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.